ArticlePLOS global public health2026
HIV epidemic in Lesotho - HIV treatment and monitoring of patients on antiretroviral therapy 2014-2024.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates progress in expanding access to antiretroviral therapy (ART) and HIV viral load (VL) monitoring in Lesotho using programmatic data 2014-2024. As a lower middle-income country in Southern Africa, Lesotho maintains the world's second highest HIV prevalence (25.6%).Retrospective, countrywide data from 2014-2024 were assessed, including the cumulative number of people living with HIV receiving ART, the proportion of ART patients who had a VL test within the prior 12 months, the percentage of VL tests indicating viral suppression (<1,000 copies/mL) and the turnaround time (TAT) from specimen collection to result return.From 2014 to 2024, the number of PLHIV on ART more than doubled, rising from 111,322-242,438. VL coverage progressed from 6% in 2014 to 93% in 2024. VL suppression improved from 75% in 2015 to 99% in 2024. Mean TAT declined from 56 to 8 days over the study period.Lesotho achieved substantial expansion of ART coverage, VL testing, and timely result reporting during the study period 2014-2024. This report documents Lesotho's achievement to reach the third UNAIDS "95" goal that 95% of persons on ART are virally suppressed. These findings underscore the feasibility of scaling up HIV service delivery, achieving high levels of viral suppression and strengthening laboratory systems in high-prevalence, resource limited countries.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.